Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Terry Sweet
Date of last notice	22 November 2018

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect.
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Sparrow Holdings Pty Ltd as trustee for the Sweet Super Fund Mr Sweet is a beneficiary of the superannuation fund and a director and shareholder of the trustee.
Date of change	4 November 2021
No. of securities held prior to change	2,348,000 fully paid ordinary shares (Shares) 200,000 unquoted options exercisable at \$0.50 per option on or before 22 November 2021 (Director A Options) 200,000 unquoted options exercisable at \$0.67 per option on or before 22 November 2022 (Director B Options).
Class	<ul><li>(a) Director A Options.</li><li>(b) Shares.</li></ul>
Number acquired	(a) Not applicable. (b) 200,000 Shares.

<sup>+</sup> See chapter 19 for defined terms.

Number disposed	<ul><li>(a) 200,000 Director A Options.</li><li>(b) Not applicable.</li></ul>
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	(a) Nil. (b) \$100,000.
No. of securities held after change	Direct Nil.  Indirect 2,548,000 Shares. 200,000 Director B Options.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ul><li>(a) Exercise of options.</li><li>(b) Issue of Shares on exercise of options.</li></ul>

#### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - \*Closed period

Were the interests in the securities or contracts	No.
detailed above traded during a +closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to allow	
the trade to proceed during this period?	
If prior written clearance was provided, on what	
date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.

Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Edward House
Date of last notice	29 June 2020

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Paul & Hannah House Enterprises Pty Ltd <paul &="" a="" c="" family="" hannah="" house=""></paul>	
interest.	Mr House is a shareholder and director of the trustee and a beneficiary of the trust.	
Date of change	4 November 2021	
No. of securities held prior to change	Direct 343,864 fully paid ordinary shares ( <b>Shares</b> ).	
	Indirect 375,000 Shares.	
	100,000 unquoted options exercisable at \$0.50 per option on or before 22 November 2021 ( <b>Director A Options</b> ).	
	100,000 unquoted options exercisable at \$0.67 per option on or before 22 November 2022 ( <b>Director B Options</b> ).	
Class	<ul><li>(a) Director A Options.</li><li>(b) Shares.</li></ul>	

<sup>+</sup> See chapter 19 for defined terms.

Number acquired	(a) Not applicable.	
	(b) 100,000 Shares.	
Number disposed	(a) 100,000 Director A Options.	
	(b) Not applicable.	
Value/Consideration	(a) Nil.	
Note: If consideration is non-cash, provide details and estimated valuation	(b) \$50,000.	
No. of securities held after change	Direct	
	343,864 Shares.	
	Indirect	
	475,000 Shares.	
	100,000 Director B Options.	
Nature of change	(a) Exercise of options.	
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(b) Issue of Shares on exercise of options.	

#### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - \*Closed period

Were the interests in the securities or contracts	No.
detailed above traded during a +closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to allow	Not applicable
the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	Not applicable

<sup>+</sup> See chapter 19 for defined terms.

Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Roger Moore
Date of last notice	29 June 2020

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect.	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Moore and Sotomi Investments Pty Ltd as trustee for the Roger Moore Family A/C  Mr Moore is a director and shareholder of the trustee and a beneficiary of the trust.	
Date of change	4 November 2021	
No. of securities held prior to change	Direct Nil.  Indirect 717,000 fully paid ordinary shares (Shares). 100,000 unquoted options exercisable at \$0.50 per option on or before 22 November 2021 (Director A Options). 100,000 unquoted options exercisable at \$0.67 per option on or before 22 November 2022 (Director B Options).	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3Y Change of Director's Interest Notice

Class	<ul><li>(a) Director A Options.</li><li>(b) Shares.</li></ul>
Number acquired	(a) Not applicable. (b) 100,000 Shares.
Number disposed	(a) 100,000 Director A Options. (b) Not applicable.
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	(a) Nil. (b) \$50,000.
No. of securities held after change	Direct Nil.
	Indirect 817,000 Shares. 100,000 Director B Options.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ul><li>(a) Exercise of options.</li><li>(b) Issue of Shares on exercise of options.</li></ul>

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 – \*Closed period

Were the interests in the securities or contracts detailed	No.
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.